Victory Capital Management Inc. Sells 155,144 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Victory Capital Management Inc. lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 71.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,387 shares of the company’s stock after selling 155,144 shares during the period. Victory Capital Management Inc. owned about 0.13% of Amphastar Pharmaceuticals worth $2,354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pacer Advisors Inc. grew its position in shares of Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after buying an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp lifted its stake in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after acquiring an additional 439,281 shares during the period. Hotchkis & Wiley Capital Management LLC bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at $10,804,000. Portolan Capital Management LLC increased its position in Amphastar Pharmaceuticals by 201.1% during the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock valued at $15,906,000 after purchasing an additional 218,901 shares during the period. Finally, Weiss Asset Management LP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth $4,967,000. Institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

AMPH has been the topic of a number of research reports. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their target price for the company from $66.00 to $36.00 in a research note on Tuesday, February 4th. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $27.69 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 12-month low of $25.89 and a 12-month high of $53.96. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 9.23, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a fifty day simple moving average of $32.58 and a two-hundred day simple moving average of $41.04.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.